Myomo (MYO) Stock Analysis & AI Equity Report
Myomo (MYO) overview
Myomo (MYO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 40.9m and operating profit of USD -14.4m; the year-end share price was 0.91 USD and market capitalisation was USD 35.0m. Myomo is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Myomo's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Myomo
Myomo develops and markets the MyoPro line of custom-fabricated, myoelectric upper-limb braces for people with neuromuscular disorders and arm paralysis. The devices use sensors to detect a wearer’s muscle signals and assist arm and hand movement. Myomo provides devices directly to patients and also sells through orthotics and prosthetics providers, the Veterans Administration, and certain international accounts.
Generate the Myomo report
Myomo is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Myomo and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Myomo
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.